The comeback kid: TYSABRI now FDA approved for Crohn disease

被引：19
作者：
Honey, Karen
机构：
来源：
JOURNAL OF CLINICAL INVESTIGATION | 2008年 / 118卷 / 03期
关键词：
D O I：
10.1172/JCI35179
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：825 / 826
页数：2
相关论文
共 6 条
[1]  
*EL PHARM INC, 2006, TUSABRI MAIN REM PAT
[2]   Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab [J].
Langer-Gould, A ;
Atlas, SW ;
Green, AJ ;
Bollen, AW ;
Pelletier, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) :375-381
[3]   A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis [J].
Polman, CH ;
O'Connor, PW ;
Havrdova, E ;
Hutchinson, M ;
Kappos, L ;
Miller, DH ;
Phillips, JT ;
Lublin, FD ;
Giovannoni, G ;
Wajgt, A ;
Toal, M ;
Lynn, F ;
Panzara, MA ;
Sandrock, AW .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) :899-910
[4]  
*US FDA, 2005, NAT INF
[5]   Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease [J].
Van Assche, G ;
Van Ranst, M ;
Sciot, R ;
Dubois, B ;
Vermeire, S ;
Noman, M ;
Verbeeck, J ;
Geboes, K ;
Robberecht, W ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) :362-368
[6]  
BIOGEN IDEC NEWS MEI
1